40 results about "Organ Specificity" patented technology

The present invention provides the use and composition of matter of angiogenic or other growth/cytokine factors expressed by mixtures of allogeneic human cell strains or lines of various types and stages of differentiation. Also provided are unencapsulated preparations (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) for the purpose of temporary application to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.

The invention provides methods for analyzing and predicting the in vivo respiratory toxicity of a compound (e.g., pharmaceutical, biological, cosmetic, or chemical compounds) or composition comprising a combination of an in vitro mammalian cell model with multiple endpoint analysis, and time and concentration response curves. The methods allow the determination of a predicted in vivo respiratory toxicity value of a compound without the use of animals, with a high degree of accuracy. The methods comprise detecting any combination of cell viability markers and expression levels of genes implicated in respiratory toxicity and/or sensitization, such as pro-inflammatory response genes, combining the viability and gene expression level data with concentration response and time response data, conducting a computational analysis, and comparing test compound data to a database of known respiratory toxicants/sensitizers to predict and/or analyze the respiratory toxicity. An indication of organ specificity is provided by a toxicity index, which is determined by comparing mean IC₅₀ values in lung cells to mean IC₅₀ values in liver cells.

Prodrugs based on gemcitabine structure shown in formula (I) as well as their synthetic method and application are disclosed in the present invention, wherein the definitions for the groups of a, b, c, d, E, Z and V are described in the specification. By modifying the N⁴ group, the solubility, the bioavailability and the organ specificity of the prodrugs are improved. Therefore, the fast metabolism problem is overcome for the produced prodrugs compounds. Intestinal toxicity induced by gemcitabine is decreased. Thereby, the prodrugs can be delivered by oral administration in clinics and further improve their anti-tumor, anti-cancer, anti-infection and diffusion preventing capability, and can also specifically act on liver or colon. The synthetic method is simple and adapted to industrial production.

The invention relates to a method and a device for detecting free epithelial cell organ sources in blood. The method includes the following steps: capturing epithelial cells from a blood sample; cracking the epithelial cells to release protein therein; specifically recognizing at least four protein markers with organ specificity; acquiring the organ sources of the epithelial cells by detecting expression quantity of the protein markers. The device comprises a microgroove chip and an antibody loading glass piece, 100-10000 microgrooves are formed in the microgroove chip and used for containing the cells, the antibody loading glass piece is used for loading an antibody micro-array which comprises at least four mutually-independent antibody strips, and the microgrooves and the antibody micro-array are arranged in a matched manner to enable at least one part of each antibody strip to be contained at corresponding positions of the microgrooves. The problem of detecting the epithelial cell organ sources in blood is solved by quickly and effectively detecting multiple proteins in single cells.

The invention relates to a promoter for the specificity expression and the later development expression of a plant tissue and application thereof, belonging to the biotechnology field. In the invention, a promoter sequence of a cotton cyclopropane fatty acid synthase with the length of 2.6kb is obtained. Place analysis proves that the promoter sequence contains a CAAT box, a TATA box, a cupric ion induced expression element, a pathogenicbacteria induced expression element, a dry response element, a cold stress response element, and the like as well as some root specificity expression elements and floral organ specificity elements. After GUS (beta-Glucuronidase) is dyed, a traditional gene is specially expressed at a later development stage by the promoter, and the expression parts are only restricted at a stem base part, a root and an anther.

The invention relates to a newly discovered DNA sequence which can be used as a promoter for regulating and controlling specific expression of a target gene in tissue organs of a plant overground part in a photoinduced form. A promoter sequence of an AtcpSecY2 gene is cloned from a model plant arabidopsis thaliana; and subsequently in a transgenic arabidopsis thaliana, the promoter is confirmed to be capable of driving a GUS reporter gene to be specifically expressed in the tissue organs of the plant overground part in the photoinduced form. With application of the promoter, a 'promoter-target gene to be expressed' fusion gene is obtained by construction, a plant is transformed, and the transgenic plant having both plant overground tissue organ specificity and photoinduced specificity expression of the target gene can be obtained. The promoter not only contributes to research on a transcription regulation expression mode of plant genes under a condition of illumination, but also is applied in plant gene engineering to allow exogenous genes to be moderately expressed along with plant physiological statuses under the condition of illumination, at the same time, accurately and effectively changes photosynthetic characteristics and agronomic characters of the plant overground part, realizes crop strain improvement, and has wide application value.

The invention belongs to the field of crop genetic breeding, and relates to a ZmCLA7-1 gene for regulating the included angle of corn leaves, in particular to a forward regulation factor for regulating and controlling the included angle of corn leaves and application thereof. Wherein the forward regulation factor is the gene ZmCLA7-1 or a promoter of the gene ZmCLA7-1, the base sequence of the gene ZmCLA7-1 is as shown in SEQ ID NO.1, the promoter sequence is as shown in SEQ ID NO.5, and the promoter of the gene ZmCLA7-1 has base mutation and insertion/deletion. RNAi technology is used for inhabiting the expression of endogenous ZmCLA7-1 gene of corn. Specifically, the ZmCLA7-1 gene is fused with other regulatory elements such as a constitutive promoter (such as a CaMV35S promoter) or an organ specific promoter to construct a gene inhibition expression vector, and a corn selfing line with a small leaf included angle and a compact plant type is created through a transgenic technology (such as antisense RNA or RNAi) and is used for cultivating a new corn density-tolerant variety.

The invention discloses a medical image multi-organ segmentation method and system. The method comprises the following steps: carrying out data preprocessing and enhancement operation on acquired to-be-segmented three-dimensional CT medical data; performing down-sampling to obtain low-resolution data, and inputting the low-resolution data into a rough stage segmentation network to obtain a down-sampling segmentation prediction result; performing up-sampling on the down-sampled segmentation prediction result to an original resolution ratio, and positioning an area of interest of the three-dimensional CT medical data by using the segmentation prediction result in the rough stage and cutting out the area of interest; inputting the region of interest into a fine stage segmentation network based on organ specificity dynamic adjustment for fine segmentation; further refining and segmenting by using an iterative refined low-confidence prediction region feature enhancement technology to obtain a segmentation result of the region of interest; processing the obtained segmentation result, the original resolution and the cutting coordinates, restoring the region of interest to the corresponding position in the complete CT, obtaining the final segmentation result through post-processing operation, and the segmentation performance and the segmentation precision are improved.

The invention provides an identification technology of a novel circulating tumor cell (CTC). The identification technology is used for identifying the CTC. The method is characterized in that body fluid (such as peripheral blood) of a tumor patient is subjected to standard sampling, transportation and storage, sample pretreatment, CTC enrichment and separation on a microfiltration film, cell immobilization, cell silver staining and immunofluorescence in-situ detection, whether the cells are tumor cells or not is determined according to the karyoplasm proportion, the irregular nucleolus characteristics and the number, and finally the organ tissue source of CTC in blood is determined through fluorescence immunoassay of tissue and organ specific protein markers. According to the method, CTC is subjected to in-situ microscopic examination, tumor cells are detected, organ tissue sources of circulating tumor cells are determined, a long-term problem that CTC morphological identification lacks a believable method is solved, and establishment of a unified standard for CTC detection is facilitated. The method has advantages of being easy to operate, good in repeatability, high in stabilityand the like, and can be used for early screening of tumor high-risk groups, curative effect evaluation of cancer patients and recurrence monitoring.

The invention relates to a nitrogen efficient fusion gene SA and application thereof. One fusion gene is constructed by way of manually splicing a source organ specific promoter and an autophagic keygene. The fusion gene is named SA, the sequence of which is as shown in SEQ ID NO.1. A plant binary expression vector can be constructed by means of the SA fusion gene and a target plant can be converted. The invention provides an embodiment in soybeans, verifying that after the SA fusion gene is transferred to the soybeans, the autophagic mediated nutrient substance remobilizing efficiency in thesource organ of transgenic soybeans can be improved specifically, and the tolerance of the transgenic soybeans to low nitrogen and low nutrient stress is improved obviously; meanwhile, the output ofthe transgenic soybeans planted in a low nitrogen condition is improved obviously. In addition, the fusion gene can be also transferred to other crops to obtain transgenic novel varieties which utilize nitrogen efficiently. The fusion gene SA has important meaning in reducing application of chemical fertilizers agriculturally, lowering the production cost and protecting the environment.

The invention discloses a corn nutritive organ specificity promoter and application thereof. The corn nutritive organ expression promoter can be expressed in corn nutritive organs and has the nucleotide sequence shown in SEQ ID NO.1. A plant expression vector with the corn nutritive organ expression promoter is provided. The plant expression vector is established by replacing a CaMV35S promoter on a plant binary expression vector pCAMBIA1301 with the corn nutritive organ expression promoter. The corn nutritive organ specificity promoter is only expressed in nutritive organs of transgenic rice (Zhonghua 11) instead of seeds and can have good application prospects in corn cultivation on the aspects of insect resistance, disease resistance and the like of transgene.

The present invention provides a method of extracting an organ- or tissue-specific highly expressed gene, including:

(1) a step for measuring expression level of a specified gene group for each organ or tissue in 2 or more individuals,

(2) a step for acquiring (a) a minimum value of expression levels in a particular organ or tissue in all individuals, and (b) a maximum value of expression levels in other organs and tissues in all individuals, for each gene, and

(3) a step for extracting the gene as a gene highly expressed specifically in the particular organ or tissue if the above-described (a)/(b) ratio is larger than 1. By the present invention, truly organ- or tissue-specific genes are extracted.

The present invention discloses DNA molecule identifying method of bluish dogbane and poacynum handersonii. The method includes the steps of extracting the genome DNA of bluish dogbane and poacynum handersonii separately, twice PCR proliferation and agarose gel electrophoresis in two different annealing temperatures with the extracted genome DNA as template and the specific primer, and identifying bluish dogbane and poacynum handersonii based on the electrophoresis behaviors of the PCR products. The method is not affected by environment factors, is independent on individual growth stages, and has no tissue and organ specificity, high repeatability, high stability and other advantages.

The present invention provides constructs and methods for increasing the content of selected amino acids by targeted expression or accumulation of amino acid sequence-rich proteins in plant species or in plant tissues or organs. Said increased levels are obtained by stably transforming plants with a recombinant nucleotide sequence construct encoding a carrier protein, having a polyamino acid extension at the 3'-end of said construct and operably linked to a tissue or on organ-specific regulatory sequences. The increased amino acid content in plant tissues, especially the membranous oil bodies and cell walls of seeds, provides a useful component for animal feed.

The invention discloses a method for making a kidney-specific drug delivery model. Compared with the prior art, the invention facilitates the reverse diffusion of the drug or the virus vector carrying the target gene through the renal pelvis, and uniformly reaches all the kidneys of the used nephron. Small tubules and glomerular capsules, drugs or target genes form a uniform therapeutic high concentration in the local kidney, and have less impact on extrarenal tissues and organs. It is an ideal kidney-targeted drug delivery method and is conducive to efficient research on chronic kidney disease. Therapeutic targets and pathogenesis. Compared with other current methods, it has the advantages of simple operation, good organ specificity, uniform distribution of drug (gene) in organs, controllable concentration, and small extrarenal impact.